Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNC Gel for Refractory Diabetic Foot Ulcer
NCT04689425Phase 3Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of umbilical cord blood mononuclear cell gel in diabetic foot ulcer (DFU), sponsored by Peking University Third Hospital. Primary endpoint: Wound area reduction rate at 1 week. Status: unknown.
02
Drugs
umbilical cord blood mononuclear cell gel
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT04689425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689425.